


3rd Cuneo City ImmunoTherapy Conference (CCITC)

Immunotherapy in Hematological Malignancies 2023

May 18-20, 2023

**Spazio Incontri Fondazione CRC
CUNEO**



Organized by Prof. Massimo Massaia, SC Ematologia AO S.Croce e Carle, Cuneo - Italy
and Centro Interdipartimentale di Biotecnologie Molecolari "Guido Tarone" (MBC), Torino - Italy



SIE – Società Italiana di Ematologia



Immunotherapy in Hematological Malignancies 2023

May 18-19-20, 2023

Elide	Azzan	Cuneo, Italy	Giovanni	Martinelli	Meldola - FC, Italy
Andrea	Bacigalupo	Rome, Italy	Massimo	Massaia	Cuneo - Turin, Italy
Maria Chiara	Bonini	Milan, Italy	Tuna	Mutis	Amsterdam, The Netherlands
Benedetto	Bruno	Turin, Italy	Sattva S.	Neelapu	Houston, USA
Carmelo	Carlo-Stella	Rozzano - MI, Italy	Fabrizio	Pane	Naples, Italy
Giulia	Casorati	Milan, Italy	Cristina	Papayannidis	Bologna, Italy
Monica	Casucci	Milan, Italy	Francesco	Passamonti	Varese, Italy
Claudio	Cerchione	Meldola - FC, Italy	Pietro	Quaglino	Turin, Italy
Vincenzo	Cerullo	Helsinki, Finland	Alessandro	Rambaldi	Bergamo, Italy
Sabina	Chiaretti	Rome, Italy	Monica	Rebora	Cuneo, Italy
Roberto	Chiarle	Boston, USA; Milan - Turin, Italy	Umberto	Ricardi	Turin, Italy
Fabio	Ciceri	Milan, Italy	Marco	Ruella	Philadelphia, USA
Daniela	Cilloni	Turin, Italy	Domenico	Russo	Brescia, Italy
Paolo	Corradini	Milan, Italy	Elisa	Scarselli	Rome, Italy
Marco	De Gobbi	Orbassano - TO, Italy	Federico	Simonetta	Geneve, Switzerland
Matteo G.	Della Porta	Rozzano - MI, Italy	Michele	Spina	Aviano - PN, Italy
Enrico	Derenzini	Milan, Italy	Pierfrancesco	Tassone	Catanzaro, Italy
Massimo	Di Nicola	Milan, Italy	David T.	Teachay	Philadelphia, USA
Francesco	Di Raimondo	Catania, Italy	Sarah	Tettamanti	Monza - MB, Italy
Gianpietro P.	Dotti	Chapel Hill, USA	Alessandro	Tonacci	Pisa, Italy
Franca	Fagioli	Turin, Italy	Angelo	Vacca	Bari, Italy
Brunangelo	Falini	Perugia, Italy	Luca A.E.	Vago	Milan, Italy
Robin	Foà	Rome, Italy	Andrea	Velardi	Perugia, Italy
Roberto	Freilone	Turin, Italy	Umberto	Vitolo	Candiolo - TO, Italy
Gianluca	Gaidano	Novara, Italy			
Sara	Galimberti	Pisa, Italy			
Roger	Geiger	Bellinzona, Switzerland			
Stefania	Gobessi	Leiden, The Netherlands			
Giorgio	Inghirami	New York, USA			
Larry	Kwak	Duarte, USA			
Marco	Ladetto	Alessandria, Italy			
Franco	Locatelli	Rome, Italy			
Tommaso	Lorenzi	Turin, Italy			
Roberto	Marasca	Modena, Italy			
Maurizio	Martelli	Rome, Italy			

- 14:00 - 14:15 Welcome
E. Azzan, M. Massaia, M. Reborà
- 14:15 - 16:30** **SESSION I**
Passive immunotherapy I: novel targets and therapeutics
M. Spina, U. Vitolo
- 14:15 - 14:35 CD123: from tagraxofusp to CAR-T
G. Martinelli
- 14:35 - 14:55 UMG1 epitope: from T-ALL to lymphoproliferative disorders
P. Tassone
- 14:55 - 15:15 CCR4/CD30: mogamulizumab/brentuximab in CTCL and beyond
P. Quaglino
- 15:15 - 15:35 CD38-targeted and other immune interventions to prevent smoldering myeloma progression
C. Cerchione
- 15:35 - 15:55 Targeting CD19: tafasitamab and beyond
E. Derenzini
- 16:00 - 16:30 *Coffee Break*

- 16:30 - 18:00** **SESSION II**
Passive immunotherapy II: bispecific & antibody-drug conjugates
M.D. Gobbi, F. Pane
- 16:30 - 16:50 Update on antibody-based therapeutics and molecular targets in AML: preclinical development and clinical progresses
C. Papayannidis
- 16:50 - 17:10 Update on cell-based therapeutics in AML: from CAR-T cells to dual CAR-CIK cells
S. Tettamanti
- 17:10 - 17:30 Immune approaches to MM: from anti-CD38 monoclonal antibodies to dual CAR-T cells targeting CD138/CD38 and BCMA/CD38
T. Mutis
- 17:30 - 17:50 Curing relapsed/refractory diffuse large B-cell lymphoma with bispecific antibodies
C. Carlo-Stella
- 17:50 - 18:10 Immune approaches to ALL
S. Chiaretti
- 18:10 - 18:40 **LECTURE I**
The evolving landscape of ALL management over the years: from conventional chemotherapy to personalized treatment
R. Foà introduced by D. Russo

09:00 - 10:40

SESSION III

Adoptive immunotherapy I: CAR-T cells

B. Bruno, M. Ladetto

09:00 - 09:20

Pre-clinical models as platform for testing immune therapies

G. Inghirami

09:20 - 09:40

New generation of CAR-T cells

G.P. Dotti

09:40 - 10:00

CAR-T for lymphomas: italian real life data

P. Corradini

10:00 - 10:20

CAR-T cells: new target antigens in Hodgkin and non-Hodgkin lymphoma

B. Falini

10:20 - 10:40

Modulation of apoptosis to enhance CAR-T immunotherapy

M. Ruella

10:40 - 11:10

Coffee Break

11:10 - 11:40

LECTURE II

CAR-T cell therapy for lymphoma: current and future trends

S. Neelapu introduced by P. Corradini

11:40 - 13:00

SESSION IV

Adoptive immunotherapy II: CAR-T cells and beyond

G. Gaidano, R. Marasca

11:40 - 12:00

CAR-CIK for ALL relapsed after allogeneic transplantation

A. Rambaldi

12:00 - 12:20

Feasibility, safety and efficacy of point-of-care manufactured CAR-T cells

S. Gobessi

12:20 - 12:40

Adoptive T-cell therapy

M.C. Bonini

12:40 - 13:00

Towards off-the-shelf adoptive immunotherapy of leukemia

G. Casorati

13:00 - 14:00

Lunch

14:00 - 15:30

SESSION V

Tools & strategies to improve the efficacy of immunotherapy

R. Freilone, U. Ricardi

14:00 - 14:20

Mechanisms of resistance to CAR-T cell therapy

F. Simonetta

14:20 - 14:40

Strategies to engineer more effective T-cells and mitigate side effects

M. Casucci

14:40 - 15:00

Machine learning and artificial intelligence in immune-mediated diseases

A. Tonacci

15:00 - 15:20

Clinical application of artificial intelligence in hematology

M.G. Della Porta

15:30 - 16:00

LECTURE III

Mathematical perspectives in the biology and therapeutics of cancer

T. Lorenzi introduced by F. Passamonti

16:00 - 16:30

Coffee Break

16:30 - 18:00

SESSION VI

From tumor vaccination to oncolytic immunotherapy and engineered bacteria: back to the future

D. Cilloni, M. Di Nicola

16:30 - 16:50

Identifying biomarkers associated with clinical response to neoantigen-based cancer vaccines

E. Scarselli

16:50 - 17:10

Novel immunotherapies to target ALK-driven tumors

R. Chiarle

17:10 - 17:30

Dressing up viruses to fool cancer: fast pipeline for precision oncolytic immunotherapy

V. Cerullo

17:30 - 17:50

Engineered bacteria for immunotherapy

R. Geiger

18:00 - 18:30

LECTURE IV

Multiplex base editing to generate CAR-T cells

D.T. Teachey introduced by M.Ruella

- 09:30 - 10:00** **LECTURE V**
The tumor microenvironment in MM: hurdles or opportunities for immunotherapy?
A. Vacca introduced by F. Di Raimondo
- 10:00 - 12:30 **SESSION VII**
Immune lessons from allo-HSCT
F. Fagioli, M. Martelli
- 10:00 - 10:20 GvHD prophylaxis in allogeneic transplantations: options and trends
F. Ciceri
- 10:20 - 10:40 The extra-value of uMRD in the allotransplant setting
S. Galimberti
- 10:40 - 11:00 Changing paradigm for GvHD prophylaxis and leukemia relapse
A. Bacigalupo
- 11:00 - 11:20 *Coffee Break*

- 11:20 - 11:40 How adoptively transferred components of the donor immune system improve outcome of haploidentical transplant for acute leukemia
A. Velardi
- 11:40 - 12:00 Leukemia immune escape after transplantation: personalized therapy and new biological insights
L.A.E. Vago
- 12:00 - 12:30 **LECTURE VI**
Breakthroughs and challenges in CAR-T cell therapies
F. Locatelli introduced by G.P. Dotti
- 12:30 - 13:00 **LECTURE VII**
Towards a personalized approach to immune therapies for cancer: one drug, one patient
L. Kwak introduced by M. Massaia
- 13:00 - 13:10 *Goodbyes and meeting close*
M. Massaia

GENERAL INFORMATION

MEETING VENUE

Spazio Incontri Fondazione CRC
Via Roma, 15
12100 Cuneo - Italy

REGISTRATION

Registration is free and can be done from the website www.ercongressi.it by May 11, 2023.

OFFICIAL LANGUAGE

English. No simultaneous translation is provided.

CME

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi Srl - ID 828 - 284173
- N. 14 CME for Physicians (disciplines: pathologic anatomy, hematology, infectious diseases, internal medicine, transfusion medicine, oncology, clinical pathology (chemical analysis laboratory and microbiology), radiotherapy), Pharmacists (other sector pharmacy, SSN public pharmacy, territorial pharmacy), Biologists, Biomedical laboratory health technician, Nurses.
- Educational Objective: linee guida-protocolli-procedure.

SCIENTIFIC SECRETARIAT

Prof. Massimo Massaia

SC Ematologia - AO S. Croce e Carle
Via Michele Coppino 26, 12100 Cuneo, Italy
Laboratorio di Immunologia
dei Tumori del Sangue (LITS)
Centro Interdipartimentale di Ricerca
in Biologia Molecolare (CIRBM)
Università degli Studi di Torino

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559
Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it